| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation. |
| Indication |
For treatment, in combination with heparin, of acute coronary syndrome, including patients who are to be managed medically and those undergoing PTCA or atherectomy. |
| Pharmacology |
Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation. When administered intravenously, tirofiban inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. When given according to the recommended regimen, >90% inhibition is attained by the end of the 30-minute infusion. Tirofiban has been recently shown in patients with unstable angina to reduce ischemic events at 48 hours following infusion when compared to standard heparin therapy. |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Biotransformation |
Metabolism appears to be limited. |
| Half Life |
2 hours |
| Protein Binding |
65% |
| Elimination |
It is cleared from the plasma largely by renal excretion, with about 65% of an administered dose appearing in urine and about 25% in feces, both largely as unchanged tirofiban. |
| Distribution |
* 22 to 42 L |
| Clearance |
* 213 - 314 mL/min [Healthy subjects]
* 152 - 267 mL/min [patients with coronary artery disease] |
| External Links |
|